# Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants

> **NCT07124468** · PHASE1 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 16 (estimated)

## Conditions studied

- Infections

## Interventions

- **DRUG:** Meropenem-Pralubactam

## Key facts

- **NCT ID:** NCT07124468
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-13
- **Primary completion:** 2025-12
- **Final completion:** 2026-02
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07124468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07124468, "Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07124468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*